The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system
Abstract
The detection of CTCs prior to and during therapy is an independent and strong prognostic marker, and it is predictive of poor treatment outcome. A major challenge is that different technologies are available for isolation and characterization of CTCs in peripheral blood (PB). We compare the CellSearch system and AdnaTest BreastCancer Select/Detect, to evaluate the extent that these assays differ in their ability to detect CTCs in the PB of MBC patients. CTCs in 7.5 ml of PB were isolated and enumerated using the CellSearch, before new treatment. Two cutoff values of ≥2 and ≥5 CTCs/7.5 ml were used. AdnaTest requires 5 ml of PB to detect gene transcripts of tumor markers (GA733‐2, MUC‐1, and HER2) by RT‐PCR. AdnaTest was scored positive if ≥1 of the transcript PCR products for the 3 markers were detected at a concentration ≥0.15 ng/μl. A total of 55 MBC patients were enrolled. 26 (47%) patients were positive for CTCs by the CellSearch (≥2 cutoff), while 20 (36%) were positive (≥5 cutoff). AdnaTest was positive in 29 (53%) with the individual markers being positive in 18% (GA733‐2), 44% (MUC‐1), and 35% (HER2). Overall positive agreement was 73% for CTC≥2 and 69% for CTC≥5. These preliminary data suggest that the AdnaTest has equivalent sensitivity to that of the CellSearch system in detecting 2 or more CTCs. While there is concordance between these 2 methods, the AdnaTest complements the CellSearch system by improving the overall CTC detection rate and permitting the assessment of genomic markers in CTCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Allard, W. J., Matera, J., Miller, M. C., Repollet, M., Connelly, M. C., Rao, C., Tibbe, A. G. J., Uhr, J. W., & Terstappen, L. W. M. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0378 · Cited by 2,542
Cited by
Circulating Tumor Cells: Liquid Biopsy of Cancer
Alix-Panabières, C., & Pantel, K. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.194258 · Cited by 1,134
Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments
Lone, S. N., Nisar, S., Masoodi, T., Singh, M., Rizwan, A., Hashem, S., El-Rifai, W., Bedognetti, D., Batra, S. K., Haris, M., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01543-7 · Cited by 819
Heerboth, S., Housman, G., Leary, M., Longacre, M., Byler, S., Lapinska, K., Willbanks, A., & Sarkar, S. (2015) · Clinical and Translational Medicine · doi:10.1186/s40169-015-0048-3 · Cited by 739
Circulating tumor cell technologies
Ferreira, M. M., Ramani, V. C., & Jeffrey, S. S. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.01.007 · Cited by 511
Size-selective collection of circulating tumor cells using Vortex technology
Sollier, E., Go, D. E., Che, J., Gossett, D. R., O'Byrne, S., Weaver, W. M., Kummer, N., Rettig, M., Goldman, J., Nickols, N., et al. (2014) · Lab Chip · doi:10.1039/c3lc50689d · Cited by 498
Metadata
- Authors
- Andreopoulou, E., Yang, L. ‐., Rangel, K. M., Reuben, J. M., Hsu, L., Krishnamurthy, S., Valero, V., Fritsche, H. A., & Cristofanilli, M.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2011-11-30
- Volume
- 130
- Issue
- 7
- Pages
- 1590-1597
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2018935795
- Cited by
- 213
- References
- 1
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system. https://app.cochat.ai/papers/10.1002/ijc.26111
- The paper
- Andreopoulou, E., Yang, L. ‐., Rangel, K. M., Reuben, J. M., Hsu, L., Krishnamurthy, S., Valero, V., Fritsche, H. A., & Cristofanilli, M. (2012). Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system. International Journal of Cancer. https://doi.org/10.1002/ijc.26111
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.